Large-scale clinical trials have demonstrated that GLP-1RAs predominantly exhibit neutral or suppressive effects on overall cancer risk, with semaglutide showing no elevated cancer incidence [14], while significant reductions have been observed in specific malignancies, particularly liver cancers and prostate cancers [13, 15]
Combining it with CJC-1295 targets fat loss from multiple mechanisms
(2021) Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial
Our team members are ready to assist
On average, research shows a 5% reduction in starting body weight after 12 weeks, with continued weight loss over six months to a year